Status:
UNKNOWN
Hemodynamic Change of Coronary Atherosclerotic Plaque After Evolocumab Treatment
Lead Sponsor:
Zibo Central Hospital
Conditions:
Atherosclerosis
Eligibility:
All Genders
18-85 years
Brief Summary
Compelling evidences indicate that lipid-lowering therapy can reduce the high-risk plaque feathers and improve the coronary flow reserve. This study is going to investigate the change of lesion-specif...
Eligibility Criteria
Inclusion
- baseline CCTA revealed at least one lesion with stenotic extent from 50% to 69% on major epicardial arteries (diameter ≧2 mm);
- patients were referred for optimal medical treatment;
- patients agreed to undergo follow-up CCTA at 1-year interval.
Exclusion
- patients had previous history of myocardial infarction or coronary revascularization;
- patients were contraindicated to the usage of iodine contrast media;
- image quality of baseline or follow-up CCTA was severely impaired (in presence of severe artifact, non-diagnostic);
- patients withdrew the informed consents during follow-up;
- patients experienced major adverse cardiac events during follow-up;
- patients refused to undergo follow-up CCTA;
- lost follow-up
Key Trial Info
Start Date :
July 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 27 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04416425
Start Date
July 30 2021
End Date
February 27 2023
Last Update
April 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zibo Central Hospital
Zibo, Shandong, China, 255036